Brief: Ryvu Therapeutics Obtains Status Of Associate Partner Within IPCEI Med4Cure

Ryvu Therapeutics SA

29/05/2024 13:45

May 29 (Reuters) - Ryvu Therapeutics SA  RVU.WA :
    * OBTAINS STATUS OF ASSOCIATE PARTNER WITHIN IPCEI MED4CURE
    * COMPANY HAS FILED PANACEA-NOVO PROJECT TO IPCEI MED4CURE
    * SEES COST OF PROJECT AT MAX. 142.5 MILLION ZLOTYS
    * SAYS COMPANY EXPECTS SIGNIFICANT PART OF PROJECT WILL MEET
INDUSTRY STUDIES CRITERIA FOR WHICH FINANCING USUALLY COVERS
75-80% OF TOTAL COSTS
    * SAYS IT FORECASTS PROJECT TO COMMENCE IN 2025 AND TO LAST
FOR
ABOUT 60-72 MONTHS
    * AIM OF PANACEA-NOVO PROJECT IS TO CREATE PLATFORM RELATED
TO
CANCER TREATMENT

Source text for Workspace:  ID:nEMbYPVJSa 
Further company coverage:  RVU.WA 

 (Reporting by Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;  +48 58 769 66 00;))